603127.SS · 昭衍新药
China A-shares · RS rating 97 · As of 2026-10-14
| Price | 48.79 CNY |
|---|---|
| 1-day change | -3.2% |
| RS rating (overall / 1M / 3M / 12M) | 97 / 95 / 92 / 86 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 48 / 57 / 40 |
| Industry group (rank) | Medical-Products (64) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | +22.6% |
| Distance from 52-week high | +9.5% |
| Market cap (USD) | $5.8B |